Table 2 ISWI subunits with high frequency mutations in malignancies
From: The emerging role of ISWI chromatin remodeling complexes in cancer
Tumor | Gene | Mutation number | Case number with mutation | Percentage (total number) |
|---|---|---|---|---|
Acinar Cell Carcinoma of the Pancreas | RBBP4 | 2 | 2 | 8.6%(23) |
BPTF | 4 | 3 | 13%(23) | |
Acral Melanoma | RSF1 | 1 | 1 | 10%(10) |
Adenoid Cystic Carcinoma | BAZ2B | 2 | 2 | 5.3%(38) |
Angiosarcoma | BPTF | 3 | 3 | 3.6%(83) |
Basal Cell Carcinoma | BAZ2B | 15 | 15 | 5.1%(293) |
BAZ2A | 18 | 14 | 4.8%(293) | |
BAZ1A | 14 | 13 | 4.4%(293) | |
BAZ1B | 13 | 13 | 4.4%(293) | |
RSF1 | 9 | 9 | 3.1%(293) | |
Bladder Cancer | BAZ2B | 29 | 25 | 6.1%(412) |
BPTF | 26 | 24 | 5.1%(474) | |
RSF1 | 18 | 17 | 4.1%(412) | |
BAZ2A | 17 | 16 | 3.9%(412) | |
Cervical Squamous Cell Carcinoma | BPTF | 13 | 12 | 4.1%(291) |
Cholangiocarcinoma | SMARCA1 | 1 | 1 | 12.5%(8) |
Colon Cancer | BPTF | 9 | 9 | 8.5%(106) |
SMARCA1 | 30 | 26 | 4.9%(534) | |
Colorectal Adenocarcinoma | SMARCA1 | 30 | 26 | 4.9%(534) |
BPTF | 26 | 26 | 4.2%(619) | |
BAZ2B | 26 | 20 | 3.7%(534) | |
RSF1 | 29 | 19 | 3.6%(534) | |
BAZ1A | 25 | 19 | 3.6%(534) | |
BAZ1B | 22 | 19 | 3.6%(534) | |
BAZ2A | 21 | 19 | 3.6%(534) | |
RBBP7 | 18 | 16 | 3.0%(534) | |
Cutaneous Squamous Cell Carcinoma | BAZ2B | 14 | 13 | 33.3%(39) |
BAZ2A | 8 | 8 | 20.5%(39) | |
BAZ1A | 8 | 5 | 12.8%(39) | |
SMARCA1 | 4 | 3 | 7.7%(39) | |
SMARCA5 | 3 | 3 | 7.7%(39) | |
RSF1 | 4 | 3 | 7.7%(39) | |
BAZ1B | 3 | 3 | 7.7%(39) | |
Desmoplastic Melanoma | BPTF | 3 | 3 | 15%(20) |
Esophageal Carcinoma | BPTF | 36 | 35 | 6.8%(518) |
BAZ2B | 25 | 22 | 4.2%(518) | |
BAZ2A | 20 | 18 | 3.5%(518) | |
SMARCA1 | 103 | 56 | 10.8%(517) | |
Gallbladder Carcinoma | BAZ2B | 2 | 2 | 6.3%(32) |
BPTF | 2 | 2 | 6.3%(32) | |
Gastric Cancer | CECR2 | 3 | 3 | 3.8%(78) |
BAZ2B | 5 | 5 | 3.4%(147) | |
Head and Neck Squamous Cell Carcinoma | BAZ2B | 18 | 17 | 3.3%(515) |
Intrahepatic Cholangiocarcinoma | BPTF | 7 | 7 | 6.8%(103) |
Liver Hepatocellular Carcinoma | BAZ2B | 3 | 3 | 6.5%(46) |
BPTF | 12 | 12 | 3.2%(373) | |
Lung Adenocarcinoma | BAZ2B | 13 | 12 | 6.7%(179) |
BAZ1A | 11 | 9 | 5.0%(179) | |
BAZ2B | 11 | 11 | 4.8%(230) | |
BPTF | 9 | 8 | 4.4%(183) | |
SMARCA1 | 7 | 7 | 3.9%(179) | |
SMARCA1 | 21 | 20 | 3.5%(566) | |
BAZ1B | 7 | 6 | 3.4%(179) | |
Lung Squamous Cell Carcinoma | BAZ2B | 28 | 27 | 5.6%(484) |
BPTF | 21 | 19 | 3.9%(484) | |
BAZ1B | 16 | 15 | 3.1%(484) | |
Lung Squamous Cell Carcinoma | SMARCA1 | 9 | 9 | 3.9%(179) |
Mantle Cell Lymphoma | BPTF | 1 | 1 | 3.4%(29) |
Metastatic Melanoma | BPTF | 22 | 17 | 11.8%(144) |
BAZ2A | 14 | 14 | 9.7%(144) | |
BAZ1A | 8 | 8 | 5.6%(144) | |
Non-Hodgkin Lymphoma | RBBP4 | 1 | 1 | 7.1%(14) |
BPTF | 18 | 18 | 3.6%(500) | |
Pleural Mesothelioma | BPTF | 1 | 1 | 4.5%(22) |
Primary Central Nervous System Lymphoma | SMARCA5 | 1 | 1 | 10%(10) |
Prostate Cancer | CHRAC1 | 1 | 1 | 3.3%(30) |
Skin Cutaneous Melanoma | BPTF | 52 | 48 | 10.9%(440) |
BAZ2A | 47 | 40 | 9.1%(440) | |
BAZ1A | 36 | 26 | 5.9%(440) | |
RSF1 | 26 | 25 | 5.7%(440) | |
SMARCA1 | 23 | 23 | 5.2%(440) | |
BAZ1B | 20 | 20 | 4.5%(440) | |
RBBP4 | 15 | 13 | 3%(440) | |
Small-Cell Lung Cancer | BPTF | 9 | 9 | 7.5%(120) |
RSF1 | 7 | 7 | 5.8%(120) | |
Stomach Adenocarcinoma | BPTF | 34 | 30 | 7.6%(395) |
BAZ1A | 16 | 16 | 4.1%(395) | |
RSF1 | 16 | 15 | 3.8(395) | |
BAZ2A | 14 | 14 | 3.5%(395) | |
Urothelial Carcinoma | BPTF | 5 | 5 | 6.9%(72) |
RSF1 | 1 | 1 | 6.3%(16) | |
Uterine Clear Cell Carcinoma | BAZ1B | 1 | 1 | 6.3%(16) |
CECR2 | 3 | 3 | 4.2%(72) | |
Uterine Corpus Endometrial Carcinoma | SMARCA1 | 103 | 56 | 10.8%(517) |
BPTF | 93 | 52 | 10.1%(517) | |
BAZ1A | 70 | 46 | 8.9%(517) | |
SMARCA5 | 64 | 42 | 8.1%(517) | |
BAZ2A | 62 | 40 | 7.7%(517) | |
RSF1 | 56 | 38 | 7.4%(517) | |
BAZ1B | 68 | 38 | 7.4%(517) | |
RBBP7 | 30 | 23 | 4.4%(517) | |
RBBP4 | 18 | 16 | 3.1%(517) |